EVENT CARDIO GROUP INC. (OTCMKTS:ECGI) Files An 8-K Financial Statements and Exhibits

EVENT CARDIO GROUP INC. (OTCMKTS:ECGI) Files An 8-K Financial Statements and Exhibits

Story continues below

Item 9.01(a) and the pro forma financial information required by
9.01(b).

Item 9.01 Financial Statements and Exhibits.

(a) Financial Statements of Business Acquired.

AMBUMED, INC.

d/b/a NATIONAL CARDIAC MONITORING CENTER

FINANCIAL STATEMENTS

December 31, 2015 and 2014

TABLE OF CONTENTS

Page
Report of Independent Registered Public Accounting Firm F-1
Balance Sheets F-2
Statements of Operations F-3
Statements of Stockholders Deficit F-4
Statements of Cash Flows F-5
Notes to Financial Statements F- 6

Lichter, Yu and Associates, Inc.

Certified Public Accountants

21031 Ventura Blvd., suite 316

Woodland Hills, California 91364

Tel (818)789-0265 Fax (818) 789-3949

Report of Independent Registered Public Accounting
Firm

Board of Directors and Stockholders of

Ambumed, Inc.

We have audited the accompanying balance sheets of Ambumed, Inc.
(the Company) as of December 31, 2015 and 2014, and the related
statements of operations, stockholders deficit, and cash flows
for each of the years ended December 31, 2015 and 2014. These
financial statements are the responsibility of the Companys
management. Our responsibility is to express an opinion on these
financial statements based on our audits.

We conducted our audits in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are
free of material misstatement. The company is not required to
have, nor were we engaged to perform, an audit of its internal
control over financial reporting. Our audit included
consideration of internal control over financial reporting as a
basis for designing audit procedures that are appropriate in the
circumstances, but not for the purpose of expressing an opinion
on the effectiveness of the companys internal control over
financial reporting. Accordingly, we express no such opinion. An
audit also includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial
statements, assessing the accounting principles used and
significant estimates made by management, as well as evaluating
the overall financial statement presentation. We believe that our
audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above
present fairly, in all material respects, the financial position
of Ambumed, Inc. as of December 31, 2015 and 2014, and the
results of their operations and their cash flows for each of the
years ended December 31, 2015and 2014, in conformity with U.S.
generally accepted accounting principles.

/s/ Lichter, Yu Associates, Inc.

Woodland Hills, California

November 18, 2016

F-1

AMBUMED, INC.

d/b/a NATIONAL CARDIAC MONITORING CENTER

Balance Sheets

As of December 31, 2015 and 2014

ASSETS
CURRENT ASSETS
Cash and cash equivalents $84,074 $33,722
Accounts receivable, net 48,130 29,768
Prepaid expenses 5,739 3,229
TOTAL CURRENT ASSETS 137,943 66,719
NON-CURRENT ASSETS
Fixed assets, net 3,202 3,369
Due from related party 15,000
Other
TOTAL NON-CURRENT ASSETS 18,202 4,036
TOTAL ASSETS $156,145 $70,755
LIABILITIES AND STOCKHOLDERS’ DEFICIT
CURRENT LIABILITIES
Accounts payable and accrued expenses $81,965 $32,969
Loan from stockholder 320,352 320,352
TOTAL NON-CURRENT LIABILITIES 402,317 353,321
STOCKHOLDERS’ DEFICIT
Common stock, $1 par value, 100,000 shares authorized,
100 shares issued and outstanding 100 100
Additional paid-in capital 15,900 15,900
Accumulated deficit (262,172) (298,566)
TOTAL STOCKHOLDERS’ DEFICIT (246,172) (282,566)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT $156,145 $70,755

The accompanying notes are an integral part of these financial
statements

F-2

AMBUMED, INC.

d/b/a NATIONAL CARDIAC MONITORING CENTER

Statements of Operations

For the Years Ended December 31, 2015 and 2014

Revenues $ 1,188,522 $ 710,784
Costs of revenue 918,671 639,562
Gross profit 269,851 71,222
Operating expenses
General and administrative 145,202 122,303
Bad debt 26,850
Rent 28,000 20,200
Professional expenses 17,600 1,948
Depreciation 3,333
Amortization 1,000
221,652 145,674
NET INCOME / (LOSS) $ 48,199 $ (74,452 )
Net earnings / (loss) per share
Basic and Diluted: $ 481.99 $ (744.52 )
Weighted average number of shares used in computing basic and
diluted net loss per share:
Basic
Diluted

The accompanying notes are an integral part of these financial
statements

F-3

AMBUMED, INC.

d/b/a NATIONAL CARDIAC MONITORING CENTER

Statements of Stockholders’ Deficit

For the Years Ended December 31, 2015 and 2014

Number of Total
Shares Common Additional Accumulated Stockholders’
Outstanding Stock Paid-in Capital Deficit Deficit
Balance at December 31, 2013 $100 $15,900 $(224,114) $(208,114)
Net loss for the year (74,452) (74,452)
Balance at December 31, 2014 100 100 15,900 (298,566) (282,566)
Net income for the year 48,199 48,199
Stockholder distributions (11,805) (11,805)
Balance at December 31, 2015 100 $100 $15,900 $(262,172) $(246,172)

The accompanying notes are an integral part of these financial
statements

F-4

AMBUMED, INC.

d/b/a NATIONAL CARDIAC MONITORING CENTER

Statements of Cash Flows

For the Years Ended December 31, 2015 and 2014

CASH FLOWS FROM OPERATING ACTIVITIES
Net income / (loss) for the year $ 48,199 $ (74,452 )
Adjustments to reconcile net income / (loss) to
net cash provided by / (used in) operating activities
Provision for doubtful accounts 26,850
Depreciation and amortization 4,000 1,223
Changes in assets and liabilities:
Accounts receivable (45,212 ) (12,174 )
Prepaid expenses (2,510 ) (3,230 )
Due from related party (15,000 )
Accounts payable and accrued expenses 48,996 11,926
17,124 (2,255 )
Net cash provided by / (used in) operating activities 65,323 (76,707 )
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of fixed assets (3,166 )
Net cash used in investing activities (3,166 )
CASH FLOWS FROM FINANCING ACTIVITIES
Loan from stockholder 65,000
Distributions to stockholders (11,805 )
Net cash (used in) / provided by financing activities (11,805 ) 65,000
NET INCREASE / (DECREASE) IN CASH 50,352 (11,707 )
CASH AT THE BEGINNING OF THE YEAR 33,722 45,429
CASH AT THE END OF THE YEAR $ 84,074 $ 33,722
Supplemental disclosure of cashflow information:
Interest payments $ $
Income taxes $ $

The accompanying notes are an integral part of these financial
statements

F-5

AMBUMED, INC.

d/b/a NATIONAL CARDIAC MONITORING CENTER

Notes to Financial Statements

Years Ended December 31, 2015 and 2014

Note A Basis of Presentation and Organization

Ambumed, Inc. (the Company) was formed in 1986 in Maryland. The
Company is doing business under the trade name of National
Cardiac Monitoring Center. The Company was formed for the purpose
of providing a range of cardiac monitoring services and support
for physicians, hospitals, scanning services and home health care
agencies and patients. The Company sells cardiac monitoring
equipment and provides 24 hour monitoring services to customers,
principally in the Mid-Atlantic region. Consequently, the
Companys ability to generate future revenues and collect the
amounts due from customers is affected by economic fluctuations
in the Mid-Atlantic region

On June 30, 2016 the stockholders sold 100% of the Companys stock
to Event Cardio Group, Inc., a publicly traded company.

The accompanying financial statements are prepared in accordance
with the accounting principles generally accepted in the United
States of America (US GAAP) and to the rules and regulations of
the Securities and Exchange Commission (SEC).

Note B Summary of Significant Accounting
Policies

Use of Estimates

The preparation of financial statements in conformity with
accounting principles generally accepted in the United States of
America requires management to make estimates and assumptions
that affect the amounts reported in the financial statements and
footnotes thereto. Actual results may differ significantly from
those estimates. The estimates underlying the Companys financial
statements relate to, among other things, the accrual for
vacation, the allowance for doubtful accounts and the valuation
of long-lived assets.

Cash and Cash Equivalents

For purposes of the statements of cash flows, the Company
considers all short-term debt securities purchased with a
maturity of three months or less to be cash equivalents. They are
carried at cost, plus accrued interest, which approximates fair
value due to the short-term nature of those instruments.

Accounts Receivable

Accounts receivable from sales of cardiac monitoring equipment
and related monitoring services are based upon contracted prices
and are carried at original invoice amount less an allowance for
doubtful accounts. Accounts receivable potentially subject the
company to concentrations of credit risk. Credit is extended
based upon managements evaluation of the customers financial
condition. Accounts receivable have been reviewed by management
and are recorded at the amounts the Company expects to collect on
balances outstanding at the time of managements evaluation.

F-6

Allowance for Doubtful Accounts

The Company maintains reserves for potential credit losses on
accounts receivable. Management reviews the composition of
accounts receivable and analyzes historical bad debts, customer
concentrations, customer credit worthiness, current economic
trends and changes in customer payment patterns to evaluate the
adequacy of these reserves. F- 6

Fixed Assets

Fixed assets are carried at cost. Depreciation on fixed assets is
provided principally on the straight line method. Estimated
useful lives range from 3 to 5 years. Expenditures for major
renewals and betterments which extend the useful lives of
property and equipment are capitalized. Expenditures for
maintenance and repairs are charged to expense as incurred.

Leased equipment meeting certain capital lease criteria is
capitalized and the present value of the related lease payments
is recorded as a liability. Amortization of capitalized lease
assets is computed on the straight-line method over the shorter
of its useful life or the initial lease term.\

The components of fixed assets consist of the following as of
December31:

Automobile $ 60,876 $ 60,876
Furniture and fixtures 29,105 28,412
Computer equipment and software 42,972 40,499
Leasehold improvements 11,264
Less: accumulated depreciation and amortization (141,015 ) (137,682 )
$ 3,202 $ 3,369

Depreciation and amortization expenses for the years ended
December31, 2015 and 2014 were $4,000 and $1,223, respectively

Income Taxes

Ambumed, Inc. elected to be taxed under the provisions of
Subchapter S since its inception. Accordingly, Ambumed, Inc. will
not pay corporate income taxes on its taxable income. Instead,
the stockholders are liable for individual income taxes on their
proportionate share of the Companys income. Accordingly, no
provision or liability for income taxes has been included in
these financial statements.

to ASC 740, Accounting for Uncertainty in Income Taxes
the accounting for uncertainties in income taxes recognized in an
enterprises financial statements and prescribes a threshold of
more-likely-than-not for recognition and de-recognition of tax
positions taken or expected to be taken in a tax return.ASC 740
also provides related guidance on measurement, classification,
interest and penalties, and disclosure.The Company is not aware
of any uncertain tax positions taken in its US federal, or
Statetax returns. If the Company incurs any penalties or interest
related to its income tax filings, it will elect to include them
as a component of operating expenses.

Advertising Costs

The Company uses only non-direct response advertising. All
advertising costs are charged to expense as incurred.

Revenue Recognition

Revenue is recognized when persuasive evidence of an arrangement
exist, delivery has occurred, the fee is fixed or determinable
and collectability is probable. Revenue is generally recognized
net of allowances for returns and any taxes collected from
customers and subsequently remitted to governmental authorities.

F-7

Costs of Revenue

Costs of revenue include payroll and payroll taxes, commissions,
supplies and costs of monitors sold during the period.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to
concentrations of credit risk are cash, accounts receivable and
other receivables arising from its normal business activities.
The Company places its cash in what it believes to be
credit-worthy financial institutions. The Company has a
diversified customer base, most of which are in Mid-Atlantic
region. The Company controls credit risk related to accounts
receivable through credit approvals, credit limits and monitoring
procedures. The Company routinely assesses the financial strength
of its customers and, based upon factors surrounding the credit
risk, establishes an allowance, if required, for uncollectible
accounts and, as a consequence, believes that its accounts
receivable credit risk exposure beyond such allowance is limited.

Risks and Uncertainties

The Company is subject to risks from, among other things,
competition associated with the industry in general, other risks
associated with financing, liquidity requirements and rapidly
changing customer requirements.

Contingencies

Loss contingencies, including litigation related contingencies,
are included in the Statements of Operations when the Company
concludes that a loss is both probable and reasonably estimable.
Legal fees related to litigation related matters are expensed as
incurred and included in the Statement of Operations under the
General and administrative line item. No amount for loss was
recorded for the year ended December 31, 2015 or 2014.

Earnings per Share

Basic earnings per share are calculated by dividing net income
available to common shareholders by the weighted average number
of common shares outstanding during the fiscal period. Diluted
earnings per share are based on the weighted average number of
common shares outstanding plus, where applicable, the additional
common shares that would have been outstanding related to
dilutive share-based awards using the treasury stock method.
Dilutive potential common shares include outstanding stock
options and unvested restricted stock awards. There were no such
outstanding stock options or unvested restricted stock awards as
of December 31, 2015 or 2014.

Impairment of Long-Lived Assets and Intangible Assets

The Company reviews long-lived assets and amortizable intangible
assets for impairment whenever events or changes in circumstances
indicate that the carrying amount of the asset may not be
recoverable. The assessment of possible impairment is based upon
the Company’s ability to recover the carrying value of the
assets from the estimated undiscounted future net cash flows,
before interest and taxes, of the related operations. The amount
of impairment loss, if any, is measured as the excess of the
carrying value of the asset over the present value of estimated
future cash flows, using a discount rate commensurate with the
risks involved and based on assumptions representative of market
participants. As of December 31, 2015 and 2014, there were no
impairment losses of long-lived assets.

F-8

Fair Value of Financial Instruments

For certain of the Companys financial instruments, including cash
and equivalents, restricted cash, accounts receivable, accounts
payable, accrued liabilities and short-term debt, the carrying
amounts approximate their fair values due to their short
maturities. ASC Topic 820, Fair Value Measurements and
Disclosures, requires disclosure of the fair value of financial
instruments held by the Company. ASC Topic 825, Financial
Instruments, defines fair value, and establishes a three-level
valuation hierarchy for disclosures of fair value measurement
that enhances disclosure requirements for fair value measures.
The carrying amounts reported in the consolidated balance sheets
for receivables and current liabilities each qualify as financial
instruments and are a reasonable estimate of their fair values
because of the short period of time between the origination of
such instruments and their expected realization and their current
market rate of interest. The three levels of valuation hierarchy
are defined as follows:

Level 1 inputs to the valuation methodology are quoted prices for
identical assets or liabilities in active markets.

Level 2 inputs to the valuation methodology include quoted prices
for similar assets and liabilities in active markets, and inputs
that are observable for the asset or liability, either directly
or indirectly, for substantially the full term of the financial
instrument.

Level 3 inputs to the valuation methodology are unobservable and
significant to the fair value Measurement.

The Company analyzes all financial instruments with features of
both liabilities and equity under ASC 480, Distinguishing
Liabilities from Equity, and ASC 815.

As of December 31, 2015 and 2014, the Company did not identify
any assets and liabilities that are required to be presented on
the balance sheet at fair value.

Recently Issued Accounting Pronouncements

In November 2015, FASB issued ASU 2015-17,Income Taxes (Topic
740): Balance Sheet Classification of Deferred Taxes
. This
ASU requires the presentation of all deferred tax assets and
liabilities as non-current in the consolidated balance sheet. The
new guidance is effective for fiscal years and interim periods
within those years beginning after December 15, 2016, with early
adoption permitted. Management elected to early adopt this new
guidance effective for the fourth quarter of fiscal year 2016 in
order to simplify the global close processes. Management is
currently evaluating this standard.

In February 2016, FASB issued ASU 2016-02,Leases (Topic
842)
. FASB issued ASU 2016-02 to increase transparency and
comparability among organizations by recognizing lease assets and
lease liabilities on the balance sheet and disclosing key
information about leasing arrangements. Certain qualitative and
quantitative disclosures are required, as well as a retrospective
recognition and measurement of impacted leases. The new guidance
is effective for fiscal years and interim periods within those
years beginning after December 15, 2018, with early adoption
permitted. Management is currently evaluating this standard.

F-9

In March 2016, FASB issued ASU 2016-08,Revenue from Contracts
with Customers (Topic 606): Principal versus Agent Considerations
(Reporting Revenue Gross versus Net)
. The amendments are
intended to improve the operability and understandability of the
implementation guidance on principal versus agent considerations.
The effective date for this ASU is the same as the effective date
for ASU 2014-09. Management is currently evaluating this
standard.

Other recent accounting pronouncements issued by the FASB,
including its Emerging Issues Task Force, the American Institute
of Certified Public Accountants, and the Securities and Exchange
Commission did not or are not believed by management to have a
material impact on the Company’s present or future financial
statements.

Note C Accounts Receivable

The Company refers all accounts greater than 90 days past due to
an outside medical collection agency. An allowance for doubtful
accounts is established based upon historical collection rates
from that outside agency. Accounts receivable and the allowance
for doubtful accounts consist of the following as of December 31:

Accounts receivable $ 74,980 $ 29,768
Less: Allowance for doubtful accounts -26,850 ( — )
Accounts receivable, net $ 48,130 $ 29,768

Note D Due From Related Party

The Company has advanced funds to a limited liability company
controlled by the owners of the Company. These funds were used to
purchase cardiac monitoring equipment. The balance does not bear
interest and has no set repayment terms.

The amounts outstanding are $15,000 and $0 at December 31, 2015
and 2014, respectively. This amount was repaid in June 2016.

Note E Loan from Stockholder

Loan from stockholder consisted of multiple unsecured advances
from the Companys majority stockholder. The balance does not bear
interest and has no set repayment terms. As part of the
securities purchase agreement dated June 30, 2016, the $320,352
balance of this loan was agreed to be contributed to capital of
the Company.

Note F Major Customers

The majority of the Companys revenues are processed through
insurance companies. Revenues from insurance companies includes
one customer that totaled approximately $397,000 and $195,000
which represent 33% and 27% of the Companys revenue for the years
ended December 31, 2015 and 2014, respectively.

Accordingly, if this customers discontinued purchasing services
from the Company, the impact would have a material adverse effect
on the Companys liquidity, financial position and results of
operation.

F-10

Note G Related Party Transactions

The Company conducts its operations in facilities owned by the
Companys majority stockholder. There is no current lease. Rent
paid to this majority stockholder was $28,000 and $20,200 for the
years ended December 31, 2015 and 2014, respectively.

Note H Subsequent Events

Management has evaluated events subsequent through November 18,
2016 for transactions and other events that may require
adjustment of and/or disclosure in such financial statements.

After the close of business on June 30, 2016, all of the
outstanding shares of the Company were acquired by Event Cardio
Group, Inc., a publicly traded company. Accordingly, beginning
July 1, 2016 the Company will operate as a wholly owned
subsidiary of Event Cardio Group, Inc.

In connection with the purchase of all outstanding shares of the
Company by Event Cardio Group, the former minority stockholder of
the Company has entered into a four year employment agreement
with the Company. The Agreement employs the former minority
stockholder as the Chief Operating Officer (COO) and Executive of
the Company. Among other things, the agreement sets the COO
salary and bonus structure and provides for equity and related
equity options in Event Cardio Group, Inc.

On July 14, 2016, Event Cardio Group entered into a lease for
6,000 square feet of office space located in Linthicum, Maryland.
The lease is for a five year term, payable in monthly
installments of $6,600, plus utilities, taxes and insurance. The
Company has provided an unconditional guarantee to the landlord
for the first 24 months should Event Cardio Group default under
the terms of the lease. The guarantee is limited to $130,000.

F-11

AMBUMED, INC.

d/b/a NATIONAL CARDIAC MONITORING CENTER

CONDENSED FINANCIAL STATEMENTS

(UNAUDITED)

June 30, 2016

TABLE OF CONTENTS

Page
Unaudited Condensed Balance Sheets F-13
Unaudited Condensed Statements of Operations F-14
Unaudited Condensed Statements of Stockholders Equity F-15
Unaudited CondensedStatements of Cash Flows F-16
Notes to Unaudited Condensed Financial Statements F- 17

F-12

AMBUMED, INC.

d/b/a NATIONAL CARDIAC MONITORING CENTER

Condensed Balance Sheets

June 30, 2016
ASSETS (Unaudited) December 31, 2015
CURRENT ASSETS
Cash and cash equivalents $96,926 $84,074
Accounts receivable, net 82,607 48,130
Prepaid expenses 5,194 5,739
TOTAL CURRENT ASSETS 184,727 137,943
NON-CURRENT ASSETS
Fixed assets, net 8,627 3,202
Due from related party 15,000
TOTAL NON-CURRENT ASSETS 8,627 18,202
TOTAL ASSETS $193,354 $156,145
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
CURRENT LIABILITIES
Accounts payable and accrued expenses $73,976 $81,965
Loan from stockholder 320,352
TOTAL CURRENT LIABILITIES 73,976 402,317
STOCKHOLDERS’ EQUITY (DEFICIT)
Common stock, $1 par value, 100,000 shares authorized,
100 shares issued and outstanding 100 100
Additional paid-in capital 336,252 15,900
Accumulated deficit (216,974) (262,172)
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT) 119,378 (246,172)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) $193,354 $156,145

The accompanying notes are an integral part of these financial
statements

F-13

AMBUMED, INC.

d/b/a NATIONAL CARDIAC MONITORING CENTER

Condensed Statements of Operations

For the Six Months Ended June 30, 2016 and 2015

(Unaudited)

Revenues $ 897,391 $ 577,637
Costs of revenue 622,528 379,676
Gross profit 274,863 197,961
Operating expenses
General and administrative 75,641 47,066
Bad debt 68,150 26,850
Rent 16,800 14,000
Professional expenses 26,820 7,559
Depreciation 1,667
Amortization
187,466 97,476
NET INCOME $ 87,397 $ 100,485
Net earnings per share
Basic and Diluted: $ 873.97 $ 1,004.85
Weighted average number of shares used in computing basic and
diluted net loss per share:
Basic
Diluted

The accompanying notes are an integral part of these
financial statements

F-14

AMBUMED, INC.

d/b/a NATIONAL CARDIAC MONITORING CENTER

Condensed Statements of Stockholders’ Equity
(Deficit)

(Unaudited)

Number of Total
Shares Common Additional Accumulated Stockholders’
Outstanding Stock Paid-in Capital Deficit Equity (Deficit)
Balance at December 31, 2015 $100 $15,900 $(262,172) $(246,172)
Net income for the year 87,397 87,397
Conversion of debt to equity 320,352 320,352
Stockholder’s distributions (42,199) (42,199)
Balance at June 30, 2016 100 $100 $336,252 $(216,974) $119,378

The accompanying notes are an integral part of these
financial statements

F-15

AMBUMED, INC.

d/b/a NATIONAL CARDIAC MONITORING CENTER

Condensed Statements of Cash Flows

For the Six Months Ended June 30, 2016 and 2015

(Unaudited)

CASH FLOWS FROM OPERATING ACTIVITIES
Net income for the period $ 87,397 $ 100,485
Adjustments to reconcile net income to
net cash provided by operating activities
Provision for doubtful accounts 68,150 26,850
Depreciation and amortization 2,001
Changes in assets and liabilities:
Accounts receivable (102,627 ) (41,801 )
Prepaid expenses 3,325
Due from related party 15,000
Accounts payable and accrued expenses (7,989 ) 9,389
(26,866 ) (236 )
Net cash provided by operating activities 60,531 100,249
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of fixed assets (5,480 ) (1,267 )
Net cash used in investing activities (5,480 ) (1,267 )
CASH FLOWS FROM FINANCING ACTIVITIES
Distributions to stockholders (42,199 ) (9,200 )
Net cash used in financing activities (42,199 ) (9,200 )
NET INCREASE IN CASH 12,852 89,782
CASH AT THE BEGINNING OF THE PERIOD 84,074 33,722
CASH AT THE END OF THE PERIOD $ 96,926 $ 123,504
Supplemental disclosure of cashflow information:
Interest payments $ $
Income taxes $ $
Non- cash investing and financing activities:
Conversion of debt to equity $ 320,352 $

The accompanying notes are an integral part of these
financial statements

F-16

AMBUMED, INC.

d/b/a NATIONAL CARDIAC MONITORING CENTER

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS

Note A Basis of Presentation and Organization

Ambumed, Inc. (the Company) was formed in 1986 in Maryland. The
Company is doing business under the trade name of National
Cardiac Monitoring Center. The Company was formed for the purpose
of providing a range of cardiac monitoring services and support
for physicians, hospitals, scanning services and home health care
agencies and patients. The Company sells cardiac monitoring
equipment and provides 24 hour monitoring services to customers,
principally in the Mid-Atlantic region. Consequently, the
Companys ability to generate future revenues and collect the
amounts due from customers is affected by economic fluctuations
in the Mid-Atlantic region.

On June 30, 2016 the stockholders sold 100% of the Companys stock
to Event Cardio Group, Inc., a publicly traded company.

These unaudited interim condensed financial statements have been
prepared by the Companys management in accordance with accounting
principles generally accepted in the United States of America
(GAAP) and in the opinion of management, contain all adjustments
(consisting of only normal recurring adjustments) necessary to
present fairly the Companys financial position, results of
operations and cash flows for the periods presented. Certain
information and note disclosures normally included in annual
financial statements prepared in accordance with GAAP have been
omitted in these unaudited interim condensed financial
statements. The results of operations, financial position, and
cash flows for the periods presented herein are not necessarily
indicative of future financial results. These unaudited interim
condensed financial statements should be read in conjunction with
the Companys December 31, 2015 financial statements and notes
thereto included in the Companys Form 8-K filed with the
Securities and Exchange Commission (SEC). The year-end condensed
balance sheet data was derived from audited financial statements,
but does not include all disclosures required by GAAP.

Note B Summary of Significant Accounting
Policies

Use of Estimates

The preparation of financial statements in conformity with
accounting principles generally accepted in the United States of
America requires management to make estimates and assumptions
that affect the amounts reported in the financial statements and
footnotes thereto. Actual results may differ significantly from
those estimates. The estimates underlying the Companys financial
statements relate to, among other things, the accrual for
vacation, the allowance for doubtful accounts and the valuation
of long-lived assets.

F-17

Cash and Cash Equivalents

For purposes of the statements of cash flows, the Company
considers all short-term debt securities purchased with a
maturity of three months or less to be cash equivalents. They are
carried at cost, plus accrued interest, which approximates fair
value due to the short-term nature of those instruments.

Accounts Receivable

Accounts receivable from sales of cardiac monitoring equipment
and related monitoring services are based upon contracted prices
and are carried at original invoice amount less an allowance for
doubtful accounts. Accounts receivable potentially subject the
company to concentrations of credit risk. Credit is extended
based upon managements evaluation of the customers financial
condition. Accounts receivable have been reviewed by management
and are recorded at the amounts the Company expects to collect on
balances outstanding at the time of managements evaluation.

Allowance for Doubtful Accounts

The Company maintains reserves for potential credit losses on
accounts receivable. Management reviews the composition of
accounts receivable and analyzes historical bad debts, customer
concentrations, customer credit worthiness, current economic
trends and changes in customer payment patterns to evaluate the
adequacy of these reserves.

Fixed Assets

Fixed assets are carried at cost. Depreciation on fixed assets is
provided principally on the straight line method. Estimated
useful lives range from 3 to 5 years. Expenditures for major
renewals and betterments which extend the useful lives of
property and equipment are capitalized. Expenditures for
maintenance and repairs are charged to expense as incurred.

Leased equipment meeting certain capital lease criteria is
capitalized and the present value of the related lease payments
is recorded as a liability. Amortization of capitalized lease
assets is computed on the straight-line method over the shorter
of its useful life or the initial lease term.

The components of fixed assets consist of the following as of
June 30, 2016 and December 31, 2015:

6/30/16

12/31/15

Automobile $ 60,876 $ 60,876
Furniture and fixtures 29,105 29,105
Computer equipment and software 49,719 42,972
Leasehold improvements 11,264 11,264
Less: accumulated depreciation and amortization (142,337 ) (141,015 )
$ 8,627 $ 3,202

F-18

Depreciation and amortization expenses for the six months ended
June 30, 2016 and 2015 were $55 and $2,001, respectively

Income Taxes

Ambumed, Inc. elected to be taxed under the provisions of
Subchapter S since its inception. Accordingly, Ambumed, Inc. will
not pay corporate income taxes on its taxable income. Instead,
the stockholders are liable for individual income taxes on their
proportionate share of the Companys income. Accordingly, no
provision or liability for income taxes has been included in
these financial statements.

to ASC 740, Accounting for Uncertainty in Income Taxes
the accounting for uncertainties in income taxes recognized in an
enterprises financial statements and prescribes a threshold of
more-likely-than-not for recognition and de-recognition of tax
positions taken or expected to be taken in a tax return.ASC 740
also provides related guidance on measurement, classification,
interest and penalties, and disclosure.The Company is not aware
of any uncertain tax positions taken in its US federal, or
Statetax returns. If the Company incurs any penalties or interest
related to its income tax filings, it will elect to include them
as a component of operating expenses.

Advertising Costs

The Company uses only non-direct response advertising. All
advertising costs are charged to expense as incurred.

Revenue Recognition

Revenue is recognized when persuasive evidence of an arrangement
exist, delivery has occurred, the fee is fixed or determinable
and collectability is probable. Revenue is generally recognized
net of allowances for returns and any taxes collected from
customers and subsequently remitted to governmental authorities.

Costs of Revenue

Costs of revenue include payroll and payroll taxes, commissions,
supplies and costs of monitors sold during the period.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to
concentrations of credit risk are cash, accounts receivable and
other receivables arising from its normal business activities.
The Company places its cash in what it believes to be
credit-worthy financial institutions. The Company has a
diversified customer base, most of which are in Mid-Atlantic
region. The Company controls credit risk related to accounts
receivable through credit approvals, credit limits and monitoring
procedures. The Company routinely assesses the financial strength
of its customers and, based upon factors surrounding the credit
risk, establishes an allowance, if required, for uncollectible
accounts and, as a consequence, believes that its accounts
receivable credit risk exposure beyond such allowance is limited.

Risks and Uncertainties

The Company is subject to risks from, among other things,
competition associated with the industry in general, other risks
associated with financing, liquidity requirements and rapidly
changing customer requirements.

F-19

Contingencies

Loss contingencies, including litigation related contingencies,
are included in the Statements of Operations when the Company
concludes that a loss is both probable and reasonably estimable.
Legal fees related to litigation related matters are expensed as
incurred and included in the Statement of Operations under the
General and administrative line item. No amount for loss was
recorded for the six months ended June 30, 2016 and 2015.

Earnings per Share

Basic earnings per share are calculated by dividing net income
available to common shareholders by the weighted average number
of common shares outstanding during the fiscal period. Diluted
earnings per share are based on the weighted average number of
common shares outstanding plus, where applicable, the additional
common shares that would have been outstanding related to
dilutive share-based awards using the treasury stock method.
Dilutive potential common shares include outstanding stock
options and unvested restricted stock awards. There were no such
outstanding stock options or unvested restricted stock awards as
of June 30, 2016 and 2015.

Impairment of Long-Lived Assets and Intangible Assets

The Company reviews long-lived assets and amortizable intangible
assets for impairment whenever events or changes in circumstances
indicate that the carrying amount of the asset may not be
recoverable. The assessment of possible impairment is based upon
the Company’s ability to recover the carrying value of the
assets from the estimated undiscounted future net cash flows,
before interest and taxes, of the related operations. The amount
of impairment loss, if any, is measured as the excess of the
carrying value of the asset over the present value of estimated
future cash flows, using a discount rate commensurate with the
risks involved and based on assumptions representative of market
participants. As of June 30, 2016 and December 31, 2015, there
were no impairment losses of long-lived assets.

Fair Value of Financial Instruments

For certain of the Companys financial instruments, including cash
and equivalents, restricted cash, accounts receivable, accounts
payable, accrued liabilities and short-term debt, the carrying
amounts approximate their fair values due to their short
maturities. ASC Topic 820, Fair Value Measurements and
Disclosures, requires disclosure of the fair value of financial
instruments held by the Company. ASC Topic 825, Financial
Instruments, defines fair value, and establishes a three-level
valuation hierarchy for disclosures of fair value measurement
that enhances disclosure requirements for fair value measures.
The carrying amounts reported in the consolidated balance sheets
for receivables and current liabilities each qualify as financial
instruments and are a reasonable estimate of their fair values
because of the short period of time between the origination of
such instruments and their expected realization and their current
market rate of interest. The three levels of valuation hierarchy
are defined as follows:

Level 1 inputs to the valuation methodology are quoted prices for
identical assets or liabilities in active markets.

Level 2 inputs to the valuation methodology include quoted prices
for similar assets and liabilities in active markets, and inputs
that are observable for the asset or liability, either directly
or indirectly, for substantially the full term of the financial
instrument.

Level 3 inputs to the valuation methodology are unobservable and
significant to the fair value measurement.

F-20

The Company analyzes all financial instruments with features of
both liabilities and equity under ASC 480, Distinguishing
Liabilities from Equity, and ASC 815.

As of June 30, 2016 and December 31, 2015, the Company did not
identify any assets and liabilities that are required to be
presented on the balance sheet at fair value.

Recently Issued Accounting Pronouncements

The Company has considered recent accounting pronouncements and
believes these recent pronouncements will not have a material
effect on the Companys financial statements.

Note C Accounts Receivable

The Company refers all accounts greater than 90 days past due to
an outside medical collection agency. An allowance for doubtful
accounts is established based upon historical collection rates
from that outside agency. Accounts receivable and the allowance
for doubtful accounts consist of the following:

June 30, December 31,
Accounts receivable $ 177,607 $ 74,980
Less: Allowance for doubtful accounts (95,000 ) (26,850 )
Accounts receivable, net $ 82,607 $ 48,130

Note D Due From Related Party

The Company has advanced funds to a limited liability company
controlled by the owner of the Company. These funds were used to
purchase cardiac monitoring equipment. The balance does not bear
interest and has no set repayment terms.

The amounts outstanding are $0 and $15,000 at June 30, 2016 and
December 31, 2015, respectively.

Note E Loan from Stockholder

Loan from stockholder consisted of multiple unsecured advances
from the Companys majority stockholder. The balance does not bear
interest and has no set repayment terms. As part of the
securities purchase agreement dated June 30, 2016, the $320,352
balance of this loan was agreed to be contributed to capital of
the Company.

Note F Major Customers

The majority of the Companys revenues are processed through
insurance companies. Revenues from insurance companies includes
one customer that totaled approximately $232,000 and $210,000
which represent 26% and 36% of the Companys revenue for the six
months ended June 30, 2016 and 2015, respectively.

Accordingly, if this customers discontinued purchasing services
from the Company, the impact would have a material adverse effect
on the Companys liquidity, financial position and results of
operation.

Note G Related Party Transactions

The Company conducts its operations in facilities owned by one of
the Companys major shareholders. There is no current lease. Rent
paid to this stockholder was $16,800 and $14,000 for the six
months ended June 30, 2016 and 2015, respectively.

F-21

Note H Subsequent Events

Management has evaluated events subsequent through November 18,
2016 for transactions and other events that may require
adjustment of and/or disclosure in such financial statements.

After the close of business on June 30, 2016, all of the
outstanding shares of the Company were acquired by Event Cardio
Group, Inc., a publicly traded company. Accordingly, beginning
July 1, 2016 the Company will operate as a wholly owned
subsidiary of Event Cardio Group, Inc.

In connection with the purchase of all outstanding shares of the
Company by Event Cardio Group, the former minority stockholder of
the Company has entered into a four year employment agreement
with the Company. The Agreement employs the former minority
stockholder as the Chief Operating Officer (COO) and Executive of
the Company. Among other things, the agreement sets the COO
salary and bonus structure and provides for equity and related
equity options in Event Cardio Group, Inc.

On July 14, 2016, Event Cardio Group entered into a lease for
6,000 square feet of office space located in Linthicum, Maryland.
The lease is for a five year term, payable in monthly
installments of $6,600, plus utilities, taxes and insurance. The
Company has provided an unconditional guarantee to the landlord
for the first 24 months should Event Cardio Group default under
the terms of the lease. The guarantee is limited to $130,000.

F-22

(b) Pro forma financial information.

EVENT CARDIO GROUP, INC.

UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET

MAY 31, 2016

Historical
‘May 31, 2016 June 30, 2016
Event Cardio Group, Inc. Ambumed, Inc. Combined Historical Pro forma Adjustments Combined Pro Forma
CURRENT ASSETS
Cash and cash equivalents $71,248 $96,926 $168,174 1 $(600,000) $(431,826)
Accounts receivables # 82,607 82,607 82,607
Prepaid expenses 387,382 5,194 392,576 392,576
TOTAL CURRENT ASSETS 458,630 184,727 643,357 43,357
NON-CURRENT ASSETS
Investment in subsidiary 1 1,300,200
2 (1,300,200)
Investment in Medpac Asia Pacific Unit Trust 206,332 206,332 206,332
Prepaid expenses – non current portion 245,278 245,278 245,278
Property and equipment, net 305 8,627 8,932 8,932
Deposit on equipment purchase 250,000 250,000 250,000
Financing costs, net 88,071 88,071 88,071
Goodwill, net 2 1,180,822 1,180,822
TOTAL NON-CURRENT ASSETS 789,986 8,627 798,613 1,979,435
TOTAL ASSETS $1,248,616 $193,354 $1,441,970 $2,022,792
CURRENT LIABILITIES
Accounts payable and accrued expenses $425,658 $73,976 $499,634 $499,634
Other payable 1 600,000 600,000
Due to related parties 41,708 41,708 41,708
TOTAL CURRENT LIABILITIES 467,366 73,976 541,342 1,141,342
NON-CURRENT LIABILITIES
Convertible note payables- related parties 1,258,053 1,258,053 1,258,053
TOTAL LIABILITIES 1,725,419 73,976 1,799,395 2,399,395

F-23

STOCKHOLDERS’ DEFICIT
Common stock 135,894 100 135,994 1 2,000
2 (100) 137,894
Additional paid in capital 4,272,653 336,252 4,608,905 1 98,200
(336,252) 4,370,853
Equity Instruments to be issued 56,451 56,451 56,451
Subscription receivable (324,427) (324,427) (324,427)
Accumulated other comprehensive income 336,600 336,600 336,600
Accumulated deficit (4,953,974) (216,974) (5,170,948) 2 216,974 (4,953,974)
TOTAL STOCKHOLDERS’ DEFICIT (476,803) 119,378 (357,425) (376,603)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT $1,248,616 $193,354 $1,441,970 $2,022,792

Pro Forma Adjustments
#1 Investment in subsidiary 1,300,200
Cash 600,000
Other payable 600,000
Common stock 2,000
Additional paid in capital 98,200
To record investment for Ambumed, Inc..Payment of cash of
$600,000, payable of balance $600,000 on the first
anniversary of acquisition and issuance of 2,000,000 shares
at $0.0501 per share
#2 Investment in subsidiary 1,300,200
Accumulated deficit 216,974
Common stock 100
Additional paid in capital 336,252
Goodwill 1,180,822
To eliminate the investment in Ambumed and to record the
goodwill.

F-24

EVENT CARDIO GROUP, INC.

UNAUDITED PRO FORMA CONDENSED COMBINED INCOME STATEMENT

For the Nine Month Period Ended May 31, 2016

Historical
‘May 31, 2016 June 30, 2016
Event Cardio Group, Inc. Ambumed, Inc. Combined Historical Pro forma Adjustments Combined Pro Forma
Revenue, net $- $897,391 $897,391 $897,391
Cost of sales 622,528 622,528 622,528
Gross profit 274,863 274,863 274,863
Operating expenses:
General and administration expenses 1,032,018 1,032,018 1,032,018
Research development – related party 640,332 640,332 640,332
Research development – other 116,079 187,466 303,545 303,545
Total operating expenses 1,788,429 187,466 1,975,895 1,975,895
Income (loss) from operations (1,788,429) 87,397 (1,701,032) (1,701,032)
Other expense
Interest expense – related parties 68,019 68,019 68,019
Interest expense – other 13,080 13,080 13,080
Amortization – loan costs 103,859 103,859 103,859
Total other expense 184,958 184,958 184,958
Net (loss) income (1,973,387) 87,397 (1,885,990) (1,885,990)
Other Comprehensive income
Foreign currency translation adjustment 233,168 233,168 233,168
Comprehensive (loss) income $(1,740,219) $87,397 $(1,652,822) $(1,652,822)
Earnings per share:
Basic $(0.01) $(0.01) $(0.01)
Diluted $(0.01) $(0.01) $(0.01)
Weighted average number of shares outstanding:
Basic 122,500,433 122,500,433 2,000,000 124,500,433
Diluted 122,500,433 122,500,433 2,000,000 124,500,433

F-25

Pro Forma Adjustments
#1 To effect shares issued upon acquisition
The Company did not include potentially dilutive shares
issued or outstanding as the effect of those shares would
have resulted in an anti dilution.

F-26

EVENT CARDIO GROUP, INC.

UNAUDITED PRO FORMA CONDENSED COMBINED INCOME STATEMENT

For the Year Ended August 31, 2015

Historical
Aug 31, 2015 Dec 31, 2015
Event Cardio Group, Inc. Ambumed, Inc. Combined Historical Pro forma Adjustments Combined Pro Forma
Revenue, net $- $1,188,522 $1,188,522 $1,188,522
Cost of sales 918,671 918,671 918,671
Gross profit 269,851 269,851 269,851
Operating expenses:
General and administration expenses 1,185,356 221,652 1,407,008 1,407,008
Research development – related party 952,188 952,188 952,188
Research development – other 270,633 270,633 270,633
Total operating expenses 2,408,177 221,652 2,629,829 2,629,829
Income (loss) from operations (2,408,177) 48,199 (2,359,978) (2,359,978)
Other expense
Interest expense – related parties 71,104 71,104 71,104
Interest expense – other 14,000 14,000 14,000
Total other expense 85,104 85,104 85,104
Net (loss) income (2,493,281) 48,199 (2,445,082) (2,445,082)
Other Comprehensive income
Foreign currency translation adjustment 98,433 98,433 98,433
Comprehensive (loss) income $(2,394,848) $48,199 $(2,346,649) $(2,346,649)
Earnings per share:
Basic $(0.03) $- $(0.02) $(0.02)
Diluted $(0.03) $- $(0.02) $(0.02)
Weighted average number of shares outstanding:
Basic 95,254,771 95,254,771 2,000,000 97,254,771
Diluted 95,254,771 95,254,771 2,000,000 97,254,771

F-27

Pro Forma Adjustments
#1 To effect shares issued upon reorganization
The Company did not include potentially dilutive shares
issued or outstanding as the effect of those shares would
have resulted in an anti dilutive.

F-28

UNAUDITED PRO FORMA COMBINED FINANCIAL
STATEMENTS

On June 30, 2016, Event Cardio Group, Inc. (the Company, we, our
or us) completed the acquisition of Ambumed, Inc. The
accompanying unaudited pro forma condensed consolidated combined
balance sheet as of May 31, 2016 presents our historical
financial position combined with Ambumed, Inc. as if the
acquisition and the financing for the acquisition had occurred on
May 31, 2016. The accompanying unaudited pro forma condensed
consolidated combined statements of operations for the nine
months ended May 31, 2016 and the year ended December 31, 2015
present the combined results of our operations with Ambumed, Inc.
as if the acquisition and the financing for the acquisition had
occurred on September 1, 2015. The historical unaudited pro forma
condensed consolidated financial information includes adjustments
that are directly attributable to the acquisition, factually
supportable and with respect to the statement of operations are
expected to have a continuing effect on our combined results. The
unaudited pro forma condensed consolidated combined financial
information does not reflect the costs of any integration
activities or benefits that may result from realization of future
cost savings from operating efficiencies, or any revenue, tax, or
other synergies that may result from the acquisition. The
unaudited pro forma condensed consolidated combined financial
information and related notes are being provided for illustrative
purposes only and are not necessarily indicative of what our
financial position or results of operations actually would have
been had we completed the acquisition at the dates indicated nor
are they necessarily indicative of the combined companys future
financial position or operating results of the combined company.

The accompanying unaudited pro forma condensed consolidated
combined financial information and related notes should be read
in conjunction with our audited consolidated financial statements
for the year ended August 31, 2015 and our unaudited condensed
consolidated financial statements as of and for the nine months
ended May 31, 2016 and Ambumed, Inc. audited financial statements
as of and for the year ended December 31, 2015 and Ambumed, Inc.
unaudited condensed consolidated financial statements as of and
for the six months ended June 30, 2016.

We prepared the unaudited pro forma condensed consolidated
combined financial information to Regulation S-X Article 11.
Accordingly, our cost to acquire Ambumed, Inc. of approximately
$1.3 million has been allocated to the assets acquired and
liabilities assumed according to their estimated fair values at
the date of acquisition. Any excess of the purchase price over
the estimated fair value of the net assets acquired has been
recorded as goodwill. The preliminary estimates of fair values
are reflected in the accompanying unaudited pro forma condensed
consolidated combined financial information. The final
determination of these fair values will be completed as soon as
possible but no later than one year from the acquisition date.
The final valuation will be based on the actual fair values of
assets acquired and liabilities assumed at the acquisition date.
Although the final determination may result in asset and
liability fair values that are different than the preliminary
estimates of these amounts included herein, it is not expected
that those differences will be material to an understanding of
the impact of this transaction to our financial results.

Note 1 Basis of presentation

The unaudited pro forma condensed combined financial statements
are based on Event Cardio Group, Inc. and its subsidiaries and
Ambumed, Inc.s historical consolidated financial statements as
adjusted to give effect to the acquisition of Ambumed, Inc.

F-29

Accounting Periods Presented

Ambumeds historical fiscal year ended on December31 and, for
purposes of the unaudited pro forma condensed combined financial
information, its historical results have been aligned to more
closely conform to the Companys August31 fiscal year end as
explained below.

The unaudited pro forma condensed combined balance sheet as of
May31, 2016 is presented as if the Ambumed acquisition had
occurred on May31, 2016, and due to different fiscal period ends,
combines the historical balance sheet of the Company at May31,
2016 and the historical balance sheet of Ambumed at June30, 2016.

The unaudited pro forma condensed combined statements of
operations of the Company and Ambumed for the nine months ended
May31, 2016 and year ended August31, 2015 are presented as if the
Ambumed acquisition had taken place on September1, 2015. Due to
different fiscal period ends, the pro forma statement of
operations for the nine months ended May31, 2016 combines the
historical results of the Company for the nine months ended
May31, 2016 and the historical results of Ambumed for the six
months ended June30, 2016.

The pro forma statement of operations of the Company and Ambumed
for the year ended August31, 2015, due to different fiscal period
ends, combines the historical results of the Company for the year
ended August31, 2015 and the historical results of Ambumed for
the year ended December31, 2015.

Note 2 Preliminary purchase price allocation

On May 31 2016, Event Cardio Group, Inc. acquired Ambumed, Inc.
for total consideration of approximately $1.3 million. The
unaudited pro forma condensed combined financial information
includes various assumptions, including those related to the
preliminary purchase price allocation of the assets acquired and
liabilities assumed of Ambumed Inc. based on managements best
estimates of fair value. The final purchase price allocation may
vary based on final appraisals, valuations and analyses of the
fair value of the acquired assets and assumed liabilities.
Accordingly, the pro forma adjustments are preliminary and have
been made solely for illustrative purposes.

The following table shows the preliminary allocation of the
purchase price for Ambumed, Inc. to the acquired identifiable
assets, liabilities assumed and pro forma goodwill:

Purchase price allocation
Total purchase price $ 1,300,200
Cash and cash equivalents 96,926
Accounts receivable 82,607
Prepaid expense 5,194
Property equipment, net 8,627
Total identifiable assets 193,354
Accounts payable and accrued expenses (73,976 )
Net assets acquired 119,378
Total proforma goodwill $ 1,180,822

F-30

Note 3 Pro forma adjustments

The pro forma adjustments are based on our preliminary estimates
and assumptions that are subject to change. The following
adjustments have been reflected in the unaudited pro forma
condensed combined financial information:

Adjustments to the pro forma condensed combined balance sheet

(1) Reflects the investment in subsidiary and the payment of
purchase price.

(2) Reflects the preliminary estimate of goodwill, which
represents the excess of the purchase price over the fair value
of Ambumed, Inc. identifiable assets acquired and liabilities
assumed as shown in Note 2.

F-31


About EVENT CARDIO GROUP INC. (OTCMKTS:ECGI)

Event Cardio Group Inc., formerly Sunrise Holdings Limited, is engaged in developing a cardiac monitoring solution based on a wireless and leadless advance cardiac monitor. The Company, through Event Cardio Group (ECG), operates in the cardiac medical devices, patient monitoring and cardiac event prediction industry. The Company’s products include Now Cardio, a cardiac monitor, which offers dual-functionality, including both holter monitoring and event recording simultaneously, and BreastCare DTS, an non-invasive and FDA (Food and Drug Administration) -cleared as an adjunct to mammography and other established procedures for the detection of breast disease, including breast cancer. The BreastCare DTS device consists of two mirror image and disposable foam pads with three wafer-thin foil sensors on each pad. The Company has exclusive right to distribute the BreastCare DTS in the United States, Canada and certain countries in Asia, including China.

EVENT CARDIO GROUP INC. (OTCMKTS:ECGI) Recent Trading Information

EVENT CARDIO GROUP INC. (OTCMKTS:ECGI) closed its last trading session down -0.0002 at 0.0144 with 33,353 shares trading hands.

An ad to help with our costs